These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17933796)

  • 1. Prolonged response to anti-tumour necrosis factor treatment with adalimumab (Humira) in relapsing polychondritis complicated by aortitis.
    Seymour MW; Home DM; Williams RO; Allard SA
    Rheumatology (Oxford); 2007 Nov; 46(11):1738-9. PubMed ID: 17933796
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-α failure in a patient with relapsing polychondritis complicated by aortitis.
    Narshi CB; Allard SA
    Rheumatology (Oxford); 2012 May; 51(5):952-3. PubMed ID: 22298790
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab.
    Mpofu S; Estrach C; Curtis J; Moots RJ
    Rheumatology (Oxford); 2003 Sep; 42(9):1117-8. PubMed ID: 12923271
    [No Abstract]   [Full Text] [Related]  

  • 4. The successful use of infliximab in resistant relapsing polychondritis and associated scleritis.
    Cazabon S; Over K; Butcher J
    Eye (Lond); 2005 Feb; 19(2):222-4. PubMed ID: 15258602
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustained response to tocilizumab in a patient with relapsing polychondritis complicated by aortitis.
    Sallés M; Mínguez S; Ros S; Tuneu R; Gelman SM
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):223. PubMed ID: 28229816
    [No Abstract]   [Full Text] [Related]  

  • 6. Fatal acute necrotizing eosinophilic myocarditis temporally related to use of adalimumab in a patient with relapsing polychondritis.
    Adamson R; Yazici Y; Katz ES; Greisman SG; Steiger D
    J Clin Rheumatol; 2013 Oct; 19(7):386-9. PubMed ID: 24048108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?
    Hernández MV; Ruiz-Esquide V; Gómez-Caballero ME; Gómez-Puerta JA; Cañete JD; Sanmartí R
    Rheumatology (Oxford); 2011 Aug; 50(8):1523-5. PubMed ID: 21593064
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of relapsing polychondritis with infliximab.
    Richez C; Dumoulin C; Coutouly X; Schaeverbeke T
    Clin Exp Rheumatol; 2004; 22(5):629-31. PubMed ID: 15485019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remission of pediatric relapsing polychondritis with adalimumab.
    Navarrete VM; Lebrón CV; de Miera FJ; Candau CP; Sarabia FN
    J Clin Rheumatol; 2014 Jan; 20(1):45-6. PubMed ID: 24356482
    [No Abstract]   [Full Text] [Related]  

  • 10. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsing polychondritis with a TNF antagonist.
    Carter JD
    J Rheumatol; 2005 Jul; 32(7):1413. PubMed ID: 15996093
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of severe MAGIC syndrome treated successfully with the tumor necrosis factor-alpha inhibitor infliximab.
    Geissal ED; Wernick R
    J Clin Rheumatol; 2010 Jun; 16(4):185-7. PubMed ID: 20414125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of adalimumab in poststreptococcal reactive arthritis.
    Sánchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N
    J Clin Rheumatol; 2007 Jun; 13(3):176. PubMed ID: 17551391
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained response to infliximab in a patient with relapsing polychondritis with aortic involvement.
    Marie I; Lahaxe L; Josse S; Levesque H
    Rheumatology (Oxford); 2009 Oct; 48(10):1328-9. PubMed ID: 19651886
    [No Abstract]   [Full Text] [Related]  

  • 16. Adalimumab for rheumatoid arthritis?
    Ebell M; Kripke C
    Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
    [No Abstract]   [Full Text] [Related]  

  • 17. Adalimumab in juvenile rheumatoid arthritis.
    de Vries MK; van der Horst-Bruinsma IE; Wolbink GJ
    N Engl J Med; 2008 Dec; 359(23):2496; author reply 2496-7. PubMed ID: 19065700
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsing polychondritis with the TNF-alpha antagonist adalimumab.
    Lahmer T; Knopf A; Treiber M; Heemann U; Thuermel K
    Clin Rheumatol; 2010 Nov; 29(11):1331-4. PubMed ID: 20495939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
    de Vries MK; Brouwer E; van der Horst-Bruinsma IE; Spoorenberg A; van Denderen JC; Jamnitski A; Nurmohamed MT; Dijkmans BA; Aarden LA; Wolbink GJ
    Ann Rheum Dis; 2009 Nov; 68(11):1787-8. PubMed ID: 19822712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.